Our partner industries
Advancing Antibody Drug Conjugates to the next generation
LinXis enables you to fully exploit your antibody library.
Lx® links to native antibodies, without the need for any modification.
Lx® offers affordable, fast and aqueous linking.
With the LinXis Lx platform you can serve all your clients.
Linking with Lx® does not affect antibody or payload function.
The Lx® platform ensures robust conjugation.
Partnering with LinXis reduces time to market.
Lx® allows for targeting of low level antigen expressing tumors.
Lx®-based ADCs enlarge the therapeutic window.